Case 3:15-cv-07378-MLC-DEA Document 48 Filed 02/05/16 Page 1 of 7 PageID: 270
`LC—DEA Document 48 Filed 02/05/16 Page 1 of 7 Page|D: 270
`Charles M. Lizza
`
`
`
`Phone:
`
`(973) 286-6715
`
`Fax:
`
`(973) 286-68l5
`
`cl izza@saul.com
`www.saul.com
`
`VIA ECF & FEDEX
`
`February 5, 2016
`
`The Honorable Douglas E. Arpert, U.S.M.J.
`United States District Court
`
`Clarkson S. Fisher Building & U.S. Courthouse
`402 East State Street
`
`Trenton, NJ 08608
`
`Q:
`
`Helsinn Healthcare S.A., et al. v. Hospira, Inc.
`Civil Action No. 15-2077 (MLC)(DEA)
`
`Helsinn Healthcare S.A., et al. v. Fresenius Kabi USA, LLC, et al.
`Civil Action No. 15-7015 (MLC)(DEA)
`
`Helsinn Healthcare S.A., et al. v. Fresenius Kabi USA, LLC, et al.
`Civil Action No. 15-7378 §MLC1jDEA)
`
`Dear Judge Arpert:
`
`This firm, together with Paul Hastings LLP and Loeb & Loeb LLP, represents Plaintiffs
`Helsinn Healthcare S.A. and Roche Palo Alto LLC (collectively, “Plaintiffs”) in the above-
`captioned matters. We write with the consent of all parties pursuant to Your Honor’s
`instructions during the January 26, 2016 Rule 16 teleconference in these matters.
`
`Enclosed is a proposed Order of Consolidation and Scheduling Order to which the parties
`have agreed and which, subject to Your Honor’s approval, will consolidate these matters for
`purposes of discovery. If the enclosed Order of Consolidation and Scheduling Order meets with
`Your Honor’s approval, the parties respectfully request that Your Honor sign and have it entered
`on the respective dockets.
`
`Thank you for Your Honor’s kind attention to these matters.
`
`ect
`
`illyyours,
`
` Re
`
`_ Mu /gt
`
`'- M. Lizza
`
`.
`
`—
`
`Z
`
`5
`
`cc:
`
`All counsel (via e-mail)
`
`One Riverfront Plaza, Suilc 1520 0 Newark, NJ 07l02-5426 _o Phone: (973) 286-6700 9 Fax (973) 286-6800
`DELAWARE
`MARYLAND
`MASSACHUSETTS
`NEW JERSEY
`NEW YORK
`PENNSYLVANIA
`WASHTNGTON. DC
`A DELAWARE LIMITED L|ABll.|TY PAR |'NERSHlP
`
`

`
`Case 3:15-cv-07378-MLC-DEA Document 48 Filed 02/05/16 Page 2 of 7 PageID: 271
`Case 3:15—cv—O7378—MLC—DEA Document 48 Filed 02/05/16 Page 2 of 7 Page|D: 271
`
`Charles M. Lizza
`
`William C. Baton
`
`Sarah A. Sullivan
`
`SAUL EWING LLP
`
`One Riverfront Plaza, Suite 1520
`Newark, NJ 07102
`(973) 286-6700
`
`Attorneys for Plaintiffs
`Helsinn Healthcare S.A. and
`
`Roche Palo Alto LLC
`
`UNITED STATES DISTRICT COURT
`
`DISTRICT OF NEW JERSEY
`
`
`HELSINN HEALTHCARE SA. and
`ROCHE PALO ALTO LLC,
`
`Civil Action No. 15-2077 (MLC)(DEA)
`
`.
`_
`Plaintiffs,
`
`(Filed Electronically)
`
`V.
`
`HOSPIRA, INC. and HOSPIRA
`
`WORLDWIDE, INC.,
`
`Defendants.
`
`
`HELSINN HEALTHCARE SA. and
`ROCHE PALO ALTO LLC,
`
`Civil Action No. 15-7015 (MLC)(DEA)
`
`Plaintiffs,
`
`(Filed Electronically)
`
`V.
`
`FRESENIUS KABI USA, LLC, EMCURE
`
`PHARMACEUTICALS LIMITED, and
`
`EMCURE PHARMACEUTICALS USA,
`
`INC.,
`
`Defendants.
`
`

`
`Case 3:15-cv-07378-MLC-DEA Document 48 Filed 02/05/16 Page 3 of 7 PageID: 272
`Case 3:15—cv—O7378—MLC—DEA Document 48 Filed 02/05/16 Page 3 of 7 Page|D: 272
`
`HELSINN HEALTHCARE S.A. and
`
`ROCHE PALO ALTO LLC,
`
`_
`_
`Plalntlffs,
`
`V.
`
`Civil Action No. 15-7378 (MLC)(DEA)
`
`(Filed Electronically)
`
`
`
`
`
`FRESENIUS KABI USA, LLC, EXELA
`
`PHARMA SCIENCES, LLC, EXELA
`PHARMSCI, INC. and EXELA
`HOLDINGS, INC.,
`
`Defendants.
`
`

`
`Case 3:15-cv-07378-MLC-DEA Document 48 Filed 02/05/16 Page 4 of 7 PageID: 273
`Case 3:15—cv—O7378—MLC—DEA Document 48 Filed 02/05/16 Page 4 of 7 Page|D: 273
`
`AND SCHEI)
`
`THIS MATTER having come before the Court for a scheduling conference pursuant to
`
`Rule 16 of the Federal Rules of Civil Procedure on January 26, 2016; and
`
`WHEREAS, Helsinn Healthcare S.A. (“Helsinn”) and Roche Palo Alto LLC (“Roche”)
`
`(collectively, “Plaintiffs”) initiated Civil Action No. 15-2077 (MLC)(DEA) alleging infringement
`
`of United States Patent Nos. 7,947,724 (“the ’724 patent”), 7,947,725 (“the ’725 patent”),
`
`7,960,424 (“the ’424 patent”), 8,598,219 (“the ’2l9 patent”), and 8,729,094 (“the ’094 patent”)
`
`by Defendants Hospira, Inc. and Hospira Worldwide, Inc. (collectively “Hospira”) by Hospira,
`
`Inc.’s submission of Abbreviated New Drug Application (“ANDA”) No. 207005 to the U.S. Food
`
`and Drug Administration for approval to engage in the commercial manufacture, use, sale, or offer
`
`for sale within the United States, or importation into the United States, of generic palonosetron
`
`hydrochloride intravenous products;
`
`WHEREAS, Helsinn and Roche initiated Civil Action No. 15-7015 (MLC)(DEA)
`
`alleging infringement of the ’724 patent, the ’725 patent, the ’424 patent, the ’219 patent, and
`
`the ’094 patent by Defendant Fresenius Kabi USA, LLC’s (“Fresenius Kabi”) submission of
`
`ANDA Nos. 206802 and 206801 and Defendants Emcure Pharmaceuticals Limited, and Heritage
`
`Pharma Labs Inc.’s (formerly known as Emcure Pharmaceuticals USA, Inc.) (collectively,
`
`“Emcure”) submission of ANDA No. 202951 to the U.S. Food and Drug Administration for
`
`approval to engage in the commercial manufacture, use, sale, or offer for sale within the United
`
`States, or importation into the United States, of generic palonosetron hydrochloride intravenous
`
`products;
`
`WHEREAS, Helsinn and Roche initiated Civil Action No. 15-7378 (MLC)(DEA)
`
`alleging (1) infringement of United States Patent No. 9,125,905 (“the ’905 patent”) by Defendants
`
`Exela Pharma Sciences, LLC (“Exela Pharma”), ExelaPharmSci, Inc. (“ExelaPharmSci”), and
`3
`
`

`
`Case 3:15-cv-07378-MLC-DEA Document 48 Filed 02/05/16 Page 5 of 7 PageID: 274
`Case 3:15—cv—O7378—MLC—DEA Document 48 Filed 02/05/16 Page 5 of 7 Page|D: 274
`
`Exela Holdings, Inc.’s (“Exela Holdings”) (together with Exela Pharma and ExelaPharrnSci,
`
`“Exe1a”) submission of NDA No. 207963 to the U.S. Food and Drug Administration for approval to
`
`engage in the commercial manufacture, use, sale, or offer for sale within the United States, or
`
`importation into the United States, of generic palonosetron hydrochloride intravenous products;
`
`and (2) infringement of the ’724 patent, the ’905 patent, and United States Patent Nos. 8,518,981
`
`(“the ’981 patent”), 8,598,218 (“the ’218 patent”), and 9,066,980 (“the ’980 patent”) by Fresenius
`
`Kabi’s submission of NDA No. 208109 to the U.S. Food and Drug Administration for approval to
`
`engage in the commercial manufacture, use, sale, or offer for sale within the United States, or
`
`importation into the United States, of generic palonosetron hydrochloride intravenous products;
`
`WHEREAS, Helsinn and Roche are no longer asserting infringement of the ’905 patent
`
`against Fresenius Kabi in Civil Action No. 15-7378 (MLC)(DEA);
`
`WHEREAS, there are common patents and common issues of fact and law with
`
`respect to some defendants and some of the actions;
`
`WHEREAS, there are no common patents or common accused products with
`
`respect to Exela and any of the other defendants or actions; and
`
`WHEREAS, consolidation of these actions through discovery may conserve the
`
`resources of the parties and the Court, and good cause exists to consolidate these actions
`
`for purposes of discovery;
`
`IT IS on this
`
`day of
`
`. 2016, HEREBY ORDERED that:
`
`1.
`
`Civil Action Nos. 15-2077 (MLC)(DEA), 15-7015 (MLC)(DEA), and 15-7378
`
`(MLC)(DEA) are consolidated pursuant to Federal Rule of Civil Procedure 42 for discovery
`
`purposes only;
`
`2.
`
`Civil Action No. 15-2077 (MLC)(DEA) is designated as the lead case;
`
`

`
`Case 3:15-cv-07378-MLC-DEA Document 48 Filed 02/05/16 Page 6 of 7 PageID: 275
`Case 3:15—cv—O7378—MLC—DEA Document 48 Filed 02/05/16 Page 6 of 7 Page|D: 275
`
`3.
`
`All future filings in the consolidated actions are to be made under Civil Action
`
`No. 15-2077, unless said filing is applicable only to an individual action, in which case said
`
`filing shall be made in that individual action only, and the Clerk of the Court shall identify on
`
`the docket of each individual case the Lead Case and the member cases;
`
`4.
`
`The following consolidated schedule shall govern these actions:
`
`Event
`
`-
`
`Exchange Initial DlSClOS1lI;S
`
`I
`
`I
`
`Date
`
`1/29/2016
`
` 5s§rE$fQtJc1”;ng M H lllll E ’ 2}2}2b? W E
`
`Defendants serve invalidity and noninfringement
`contentions, and produce underlying documents
`
`Submit Discovery Confidentiality Order to Court
`
`Plaintiffs serve infringement contentions and
`responses to invalidity contentions, and produce
`underlying documents
`
`I
`
`I
`
`Exchange claim terms to be construed
`
`Exchange preliminary claim constructions and
`identify/designate all evidence each party intends to
`rely upon to support their proposed constructions
`
`Exchange identification of all intrinsic and extrinsic
`evidence each party intends to rely upon to oppose
`other party’s proposed constructions
`
`_
`
`_
`
`2/9/2016
`
`2/25/2016
`
`3/25-/2016-
`
`4/8/2016
`
`4/29/2016
`
`5/13/2016
`
`Joint Claim Construction and Prehearing Statement
`
`5/31/2016
`
`Complete all claim construction fact discovery
`
`-
`
`_ _
`
`_ 6:/3()fi/2016
`
`F‘——m
`
`Opening Markman briefs
`
`7/15/2016
`
`Complete expert discovery relating to claim
`construction
`
`_ - _ - H —8/l-5/;l6- ‘ — ‘flu
`
`

`
`Case 3:15-cv-07378-MLC-DEA Document 48 Filed 02/05/16 Page 7 of 7 PageID: 276
`Case 3:15—cv—O7378—MLC—DEA Document 48 Filed 02/05/16 Page 7 of 7 Page|D: 276
`
`5.
`
`If any party believes that the consolidation is adversely affecting their
`
`interests, they may petition to the Court seeking withdrawal from the consolidated actions.
`
`6.
`
`A status teleconference is scheduled for April
`
`, 2016 at
`
`a.m./p.m.
`
`Plaintiffs’ counsel shall initiate the call; and
`
`7.
`
`An in-person status conference is scheduled for August
`
`, 2016 at
`
`a.m./p.m.
`
`HONORABLE DOUGLAS E. ARPERT
`
`UNITED STATES MAGISTRATE JUDGE